Search & Filter

NICE has recommended adalimumab (Humira) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy, as per the marketing authorisation for adalimumab. Following this recommendation suitable patients in England and Wales should be able to access adalimumab on the NHS. 

Vifor Fresenius Medical Care Renal Pharma, a common company of Galenica and Fresenius Medical Care, and OPKO Health, have entered into a collaboration and license agreement for the development and commercialisation of Rayaldee in Europe, Canada, Mexico, Australia, South Korea and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency.

World Ovarian Cancer Day is May 8 and people across the world are encouraged to raise awareness about ovarian cancer. This year the theme is Know Now and the campaign will run April 25 through May 8.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has accepted six new medicines at its April meeting.

Research from Cass Business School and the International Longevity Centre-UK (ILC-UK) has found growing inequalities in adult life expectancy.  It found that while people in the UK are living longer than ever, the gap between the longest and shortest lifespans appears to be increasing.

A team from Universite Paris-Saclay have discovered a gene that makes some cancer patients more sensitive to radiotherapy. The discovery means that medicine could be personalised to save people's skin and continue treatment they may have stopped due to pain.

NICE has recommended new heart failure drug sacubitril valsartan (Entresto, Novartis), the first drug of its kind, as an option for some people with heart failure.

New research, published in the journal Vaccine, suggests that administering vaccinations in the morning, rather than the afternoon, could induce greater, and thus more protective, antibody responses.

A study, published this week in the European Heart Journal, showed that for every 100 people eating the highest proportion of healthy Mediterranean foods, there were three fewer heart attacks, strokes or deaths compared to 100 people eating the least amount of healthy foods during nearly four years of follow-up from the time the participants joined the study.

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Relypsa have submitted Marketing Authorisation Application (MAA) requesting European approval of patiromer for the treatment of hyperkalemia.

Two young inventors were recognised at last night's AXA PPP Health Tech & You Awards for inventions that could help revolutionise the lives of people living with Parkinson's disease.

A new long-term analysis detailing 10 years of clinical efficacy of alemtuzumab (Lemtrada) in people with relapsing-remitting multiple sclerosis (RRMS) were presented at the 68th American Academy of Neurology (AAN) 2016 Annual Meeting in Vancouver, Canada.

Nearly two fifths of people with Parkinson's have felt the need to hide their symptoms or lie about having the condition. This is according to new research, conducted by ComRes on behalf of Parkinson's UK to mark Parkinson's Awareness Week 2016.

A new test to help people with chronic abdominal symptoms determine whether the pain is IBS has been launched.

Data presented at the 68th American Academy of Neurology 2016 Annual Meeting in Vancouver, Canada, supports the use of Lemtrada (alemtuzumab) in the treatment of relapsing-remitting multiple sclerosis (RRMS), pharma Sanofi Genzyme has announced.